Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Improving Brain Tumor Segmentation at the Edge

Intel’s Abhishek Khowala, principal health AI engineer, and Séverine Habert, AI engineering manager, discuss some of the enhancements in brain tumor segmentation for enabling diagnosis. While most brain tumors are benign, early detection is critical for the best treatment options and outcomes. Assessing a diagnosis starts with MRI 2D and 3D imaging. Segmentation of…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Intel’s Abhishek Khowala, principal health AI engineer, and Séverine Habert, AI engineering manager, discuss some of the enhancements in brain tumor segmentation for enabling diagnosis.

While most brain tumors are benign, early detection is critical for the best treatment options and outcomes. Assessing a diagnosis starts with MRI 2D and 3D imaging. Segmentation of the brain tumor – or separating the tumor from normal brain tissues – is essential to identifying three key factors to allow doctors to move forward:

  1. Is the tumor benign or malignant?
  2. The approximate tumor size and location.
  3. Plan out the treatment options.

“We need to segment out the tumor from the rest of the tissues around it,” Khowala says. “For that, there is the unit model. And that architecture works with fewer amounts of data yet provides a clearer segmentation result.”

The brain tumor segmentation (BraTS) combined with OpenVINO™ toolkit could optimize MRI results during tumor detection and monitoring. “Since this is something that has to happen worldwide, we need to deploy it at scale,” Khowala explains. Scaling requires overcoming a few challenges. Utilizing OpenVINO erases issues of high-cost GPU required for deploying AI solutions or perceived performance limitations of common frameworks such as PyTorch or TensorFlow. “Brain tumor segmentation is a perfect example of applying the most common architecture and using it for multiple devices from edge to handheld devices,” Habert adds.

For optimized AI, the provided data must be robust, which is not an easy task. According to Khowala, Expert radiologists are required to interpret the MRI images to get to the ground truth data. BraTS helps predict results and compare accuracy with provided ground truth results using the Sørensen–Dice coefficient datasets. Once the data is available, modeling can take place and assist medical professionals in their diagnosis.

Learn more about brain tumor segmentation solutions by connecting with Abhishek Khowala and Séverine Habert on LinkedIn or visit:

https://www.intel.com/content/www/us/en/healthcare-it/healthcare-overview.html.

Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Wearables, AI diagnostics, and cybersecurity converge as healthcare's operational pressure points in 2026

Wearables, AI diagnostics, and cybersecurity converge as healthcare's operational pressure points in 2026

Wearable technology, AI diagnostics, and cybersecurity are becoming critical operational areas in healthcare by 2026. Companies like Samsung and GE HealthCare are advancing in these fields with new technologies, while cybersecurity incidents like the AnMed attack highlight the vulnerabilities in health systems. Healthcare providers must prioritize innovation and security to adapt to these emerging challenges.

  • 01Samsung's FDA-cleared Galaxy Ring represents an advancement in wearable health technology.
  • 02GE HealthCare has introduced a new AI-enabled ultrasound system.
  • 03The AnMed cyberattack underscores the urgent need for robust cybersecurity measures in healthcare.

Aug 13, 2026

TSP: Yvonne Commodore-Mensah

TSP: Yvonne Commodore-Mensah

The article discusses topics within the healthcare industry, focusing on contributions and insights from professionals in the field. It may delve into innovative practices or emerging trends shaping the sector. The discussion could also include expert opinions and potential strategies for improvement.

Aug 13, 2026

AI is compressing drug discovery timelines from years to months, and clinical operators need to prepare now

AI is compressing drug discovery timelines from years to months, and clinical operators need to prepare now

Generative AI is accelerating drug discovery processes, significantly reducing timelines from years to mere months. Clinical operators must adapt to this rapid change as AI-designed solutions become integral to the healthcare pipeline.

  • 01Generative AI is capable of reducing drug discovery timelines from years to months.
  • 02The integration of AI into healthcare is necessitating changes in clinical operations.
  • 03AI-informed patients are becoming more common in clinical settings.

Aug 12, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512